Treatments for Keratosis Pilaris
Keratosis pilaris is a very common genetic follicular disorder manifested by the appearance of rough bumps on the skin, more commonly known as "chicken skin" or "goose bumps".
Prescription treatment options to treat keratosis pilaris are topical corticosteroids, retinoids, urea, and topical immunomodulators. Topical prescription corticosteroids, like triamcinolone 1% or desonide 0.05%, can be useful if over-the-counter products are found to be ineffective against inflammation. Prescription topical solutions should be applied 2 to 4 times a day as a thin layer that is spread onto the afflicted area. Like softer concentrations of hydrocortisone, caution should be used with the prescription agents. Also, prescription-strength hydrocortisone may inhibit collagen synthesis and thereby lead to skin striate.
Concentrations of urea over 30% can be used to alleviate rough portions of the dermis. However, the urea concentration contained in the legend products is commonly sensitizing and not a popular choice.
Topical retinoids used in the treatment of keratosis pilaris involve adapalene, tazarotene, and tretinoin. Their method of action can be to increase turnover of follicular epithelial cells. These agents should be applied as a thin layer to dry skin, at bedtime, to no more than 20% of the body's surface. The adverse effects of redness, extreme dryness, and peeling are in some cases rate-limiting effects for most patients. However, some topical retinoids are available in reduced concentrations or in an emollient cream base when compared to the original products.
Contact of the retinoid with the eyes and mouth should be avoided. Also avoid exposure to UV light. Just like the AHAs, topical retinoids should be initially used every other day with a small-concentration solution and elevated to higher concentrations as tolerated. Burning and pruritus are commonly seen in the first month and commonly lessen with time. Topical retinoids are teratogenic and should not be used by women of childbearing age. One solution's package insert suggests female patients should start therapy during a normal menstrual period. Prescribing data also states that children under the age of 12 should not use topical retinoids.
Topical immunomodulators, pimecrolimus, and tacrolimus can also be of benefit if other treatments have been ineffective. However, a public health advisory has been issued by the FDA about a potential risk of skin cancer with the use of topical immunomodulators for the treatment of eczema.
These products should be applied twice daily to the afflicted areas. If a moisturizer is also being used, the patient should be instructed to use the moisturizer after pimecrolimus. Patients should be cautioned to avoid exaggerated exposure to sunlight.
Patients can initially complain of a sensation of warmth or burning and skin irritation, especially during the first week of use. Most of these reactions will commonly subside five to seven days after treatment. An advantage of the local immunomodulators is that their use is indicated for children 2 years of age and older.
Another advantage is that these elements do not impede collagen production and won't cause skin thinning. Occlusive dressings should be avoided with these agents. These agents should not be used in patients with a compromised immune system or during pregnancy since there are no complete and well-controlled researches of topically applied agents during pregnancy.
A new skin care product offers the opportunity to eliminate scars, imperfections and several skin conditions thanks to biological components that regenerate and heal your skin.
Published January 10th, 2008